# Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

> **NCT03356444** · PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Prostate Cancer
- Castration-resistant Prostate Cancer
- Drug

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03356444
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356444, "Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03356444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*